Figure 2
From: Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment
Observed changes in CA 15-3 levels in patients with de novo disease progression from baseline to 4th treatment (n = 32).
Figure 2 | BMC Cancer